# Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct07590934/  
OnCo record `nct07590934` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT07590934 as recruiting, last updated 2026-08-27. Enrolment is 152 planned participants, an estimate. Interventions: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Primary measures include Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs); Part A: Number of participants with dose limiting toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: PROSPECTOR
- Tags: ctgov-ingest
- Registry id: NCT07590934
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT07590934: https://clinicaltrials.gov/study/NCT07590934

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [FPI-2265](https://onco.cc/drugs/fpi-2265/), [Palacaparib](https://onco.cc/drugs/palacaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07590934.json